New Retina Radio by Eyetube

Latest Episodes:

Keeping Patients at the Center of GA Therapy: Patient Education and Setting Expectations Oct 02, 2025

Show notes

How do you educate and empower patients to make informed decisions about geographic atrophy (GA) therapy? In episode 2 of this New Retina Radio miniseries, moderator John Kitchens, MD guides Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD, through practical strategies for patient education. The panel covers plain-language analogies for GA, using OCT and fundus photos, coordinating with optometry, and setting realistic expectations for FDA-approved treatments. They also tackle real-world barriers—visit burden, transportation, and costs—sharing tips on benefits investigations, manufacturer portals, and charity-care pathways.
This content is editorially independent, supported by Astellas Pharma.

Keeping Patients at the Center of GA Therapy: Social Impact and Early Intervention Oct 02, 2025

Show notes

What does it mean to truly keep patients at the center of geographic atrophy (GA) therapy? In this first episode of a four-part New Retina Radio miniseries, moderator John Kitchens, MD, leads a discussion with experts Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD. The panel explores the social impact of GA and highlight the importance of early intervention, imaging, and patient education. Gain key insights into how clinicians can support patients navigating GA’s challenges.
This content is editorially independent, supported by Astellas Pharma.

New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab Sep 26, 2025

Show notes

What happens when patients with neovascular age-related macular degeneration (nAMD) show suboptimal response to faricimab (Vabysmo, Genentech/Roche) and are switched to high-dose aflibercept (Eylea HD, Regeneron)? Ben Young, MD, moderates a discussion with Pheobe Mellen, MD, and Jordan Deaner, MD, exploring real-world outcomes from a retrospective study of 135 eyes. The group dives into the implications for clinical practice and tries to parse apparently conflicting data regarding anatomic changes. Drs. Mellen and Deaner reflect on their own approaches to treating recalcitrant cases and debate what this paper means for the future of anti-VEGF therapy.

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR Sep 04, 2025

Show notes

What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression. David Lally, MD, shares results from the ReCLAIM-2 study, the phase 2 trial that assessed elamipretide (Stealth BioTherapeutics) in patients with non-central GA. What positive treatment effects were observed? And Ehsan Rahimy, MD, reviews findings from a retrospective analysis seeking to understand if continuous glucose monitoring could reduce the risk of NPDR progressing to more serious conditions. Listen in to learn what he and his colleagues found.

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders Aug 21, 2025

Show notes

Time flies: Some wet AMD patients have had the Port Delivery System with Ranibizumab (Susvimo, Genentech/Roche) for more than 5 years. How well does vision hold up at 5 years? And how do those numbers compare to 5-year endpoints in injection-based studies? John Kitchens, MD, reviews the dynamics around the PORTAL study, which assessed outcomes after 5 years of PDS treatment. And Krishna Mukkamala, MD, reviews data from a first-ever study validating longitudinal performance of AI-based home OCT (Scanly Home OCT, Notal Vision) compared with human experts. Just how sensitive and specific was home OCT compared with human graders?

New Retina Radio Journal Club w/ VBS: Obstructive Sleep Apnea and Diabetic Retinopathy Aug 13, 2025

Show notes

What happens when two systemic diseases collide? In this episode of New Retina Radio Journal Club with VBS, moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to discuss a new retrospective cohort study by Rahimy et al. The panel explores how obstructive sleep apnea impacts the progression of diabetic retinopathy and elevates the risk for systemic vascular events such as stroke, heart attack, and death. With nearly 24,000 patients analyzed, the study sheds light on the importance of screening and managing comorbidities in patients with nonproliferative diabetic retinopathy—and raises critical questions about what role retina specialists should play in addressing them.

The State of Geographic Atrophy Around the Globe: Part 2 of 2 Jul 21, 2025

Show notes

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatments. This podcast is part 2 of 2.

The State of Geographic Atrophy Around the Globe: Part 1 of 2 Jul 21, 2025

Show notes

The State of Geographic Atrophy Around the Globe: Part 1 of 2
DES: For what pathophysiologic reasons is targeting the complement pathway a viable therapeutic route for treating geographic atrophy? And which pipeline therapeutic approaches could be useful to patients in the future? Anat Loewenstein, MD is joined by a world-class trio of retina specialists—Daniel Ting, MD, PhD; Paulo Eduardo Stanga, MD; and Patricio G. Schlottmann, MD—for a discussion exploring the state of play in GA from a global perspective. This podcast is part 1 of 2.

Diabetic Retinopathy Severity and Income Status Jul 18, 2025

Show notes

Are patients from lower-income households more likely to present with severe diabetic retinopathy (DR)? Ben Young, MD, moderates a discussion with Phoebe Mellen, MD, and Jordan Deaner, MD, about a new retrospective cohort study from the Duke Eye Center than examines differences in DR severity at presentation between patients from the lowest- and highest-income ZIP codes, explores how income-based barriers to care may impact disease progression, and discusses how this data might affect clinical care, screening strategies, and public health priorities.

GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy Jul 07, 2025

Show notes

What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment? In part 2 of this 2-part series, moderator Judy Kim, MD, and panelists Rishi Singh, MD; Deepak Sambhara, MD, and Sunir Garg, MD, examine answers to these questions.

Our TOPPODCAST Picks

Follow Us

Stay Connected

New Retina Radio by Eyetube

Related Podcasts

Links

Stay Connected